Want to see INM full AI Analyst Report?
Top Page
InMed Pharmaceuticals
(NASDAQ:INM)
Select Model
Select Model
Rating:43Neutral
Price Target:
$1.50
▲(4.17% Upside)
Action:Reiterated
Date:09/10/26
The score is primarily held down by weak financial performance—persistent losses and ongoing cash burn (especially the severe 2026 cash flow deterioration). Technicals also reflect weak momentum with the stock below key moving averages. Corporate events provide some offset through merger progress, large financing, and restored Nasdaq compliance, but valuation support is limited given negative earnings and no dividend yield data.
Positive Factors
Low leverage
Very low leverage, including zero reported total debt in 2026, gives the company greater financial flexibility than a highly indebted biotech. This reduces mandatory financing pressure and leaves more room to pursue research, transactions, or other strategic priorities.
Negative Factors
Persistent net losses
Persistent and substantial net losses show that the company has not yet established a profitable operating model. The very large 2026 loss weakens retained value and means future progress remains dependent on successful development, financing, or strategic execution.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage
Very low leverage, including zero reported total debt in 2026, gives the company greater financial flexibility than a highly indebted biotech. This reduces mandatory financing pressure and leaves more room to pursue research, transactions, or other strategic priorities.
Read all positive factors
InMed Pharmaceuticals Key Performance Indicators (KPIs)
Any
Revenue By Segment
Shows how much revenue each business segment generates, highlighting the company's strengths and potential areas for growth or concern based on segment performance.
Shows how much revenue each business segment generates, highlighting the company's strengths and potential areas for growth or concern based on segment performance.
Data provided by:
The Fly
The FlyInMed Pharmaceuticals (INM) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$4.34M
Dividend YieldN/A
Average Volume (3M)85.88K
Price to Earnings (P/E)―
Beta (1Y)2.68
Revenue Growth-60.74%
EPS Growth66.05%
CountryUS
Employees13
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-1022.64
Shares Outstanding3,314,063
10 Day Avg. Volume51,999
30 Day Avg. Volume85,879
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
InMed Pharmaceuticals Business Overview & Revenue Model
Company Description
InMed Pharmaceuticals Inc. operates as a clinical-stage pharmaceutical firm, concentrating its efforts on the investigation and creation of therapeutic solutions derived from cannabinoids. Its primary product, INM-755, is a cannabinol-infused topi...
How the Company Makes Money
null...
InMed Pharmaceuticals Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
58
Neutral
Cash Flow
14
Very Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 3.18B | 4.94M | 4.60M | 4.14M | 1.09M |
| Gross Profit | 709.84M | 1.71M | 1.10M | 1.40M | 543.55K |
| EBITDA | -1.19B | -7.26M | -7.06M | -7.34M | -18.09M |
| Net Income | -1.19B | -8.16M | -7.68M | -7.95M | -18.60M |
Balance Sheet | |||||
| Total Assets | 3.03B | 21.23M | 16.17M | 18.69M | 16.46M |
| Cash, Cash Equivalents and Short-Term Investments | 2.23B | 15.09M | 8.99M | 11.81M | 8.01M |
| Total Debt | 0.00 | 1.01M | 1.32M | 518.92K | 1.02M |
| Total Liabilities | 1.96B | 2.92M | 3.58M | 2.67M | 4.78M |
| Stockholders Equity | 1.08B | 18.30M | 12.59M | 16.02M | 11.69M |
Cash Flow | |||||
| Free Cash Flow | -8.64B | -7.77M | -7.00M | -7.45M | -15.62M |
| Operating Cash Flow | -8.64B | -7.77M | -6.99M | -7.28M | -15.58M |
| Investing Cash Flow | 0.00 | 0.00 | -9.29K | -661.80K | -673.00K |
| Financing Cash Flow | 94.50M | 12.27M | 4.65M | 10.68M | 15.07M |
InMed Pharmaceuticals Technical Analysis
Negative
1.44
Price Trends
1.50
Negative
1.35
Negative
1.18
Positive
Market Momentum
-0.05
Positive
38.78
Neutral
18.10
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INM, the sentiment is Negative. The current price of 1.44 is above the 20-day moving average (MA) of 1.41, below the 50-day MA of 1.50, and above the 200-day MA of 1.18, indicating a neutral trend. The MACD of -0.05 indicates Positive momentum. The RSI at 38.78 is Neutral, neither overbought nor oversold. The STOCH value of 18.10 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for INM.
InMed Pharmaceuticals Risk Analysis
InMed Pharmaceuticals disclosed 82 risk factors in its most recent earnings report. InMed Pharmaceuticals reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
InMed Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $3.62M | -0.44 | -131.35% | ― | -50.79% | -180.59% | |
44 Neutral | $6.51M | -0.09 | -168.05% | ― | ― | 87.05% | |
43 Neutral | $4.34M | >-0.01 | 191.57% | ― | -60.74% | 66.05% | |
43 Neutral | $6.45M | -0.34 | -160.28% | ― | -84.26% | 14.73% | |
42 Neutral | $4.82M | -0.34 | -73.68% | ― | ― | 68.55% |
* Healthcare Sector Average
INM
InMed Pharmaceuticals
1.31
-0.83
-38.79%
GLMD
Galmed Pharmaceuticals
4.03
-8.05
-66.64%
CLGN
Collplant Holdings
3.54
-22.66
-86.49%
ENVB
Enveric Biosciences
1.46
-10.18
-87.45%
SILO
Silo Pharma
2.10
-7.71
-78.57%
ADXN
Addex Therapeutics
3.39
-7.31
-68.32%
InMed Pharmaceuticals Corporate Events
Business Operations and StrategyDelistings and Listing ChangesM&A TransactionsPrivate Placements and Financing
Mentari merger financing reshapes InMed Pharmaceuticals’ future
Positive
Jul 22, 2026
On July 22, 2026, Mentari Therapeutics announced a $200 million private placement of common stock and pre-funded warrants to leading healthcare investors, including Blackstone, RTW Investments and others. The financing, arranged alongside a previo...
Business Operations and StrategyM&A TransactionsRegulatory Filings and ComplianceShareholder Meetings
InMed amends merger terms, advances Mentari transition
Positive
Jul 10, 2026
On July 6, 2026, InMed Pharmaceuticals and Mentari Therapeutics amended their all-stock merger agreement to refine the sequencing of transaction steps, including an InMed name change to Mentari Therapeutics and redomestication to Nevada on closing...
Delistings and Listing ChangesRegulatory Filings and Compliance
InMed Pharmaceuticals Regains Nasdaq Listing Compliance Status
Positive
Jun 10, 2026
InMed Pharmaceuticals Inc., a developer of small molecule therapies targeting CB1/CB2 receptors with programs in Alzheimer’s, ocular and dermatological diseases, has clarified its Nasdaq listing status following earlier compliance concerns. ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.